Literature DB >> 27456163

Hydrophobic-core PEGylated graft copolymer-stabilized nanoparticles composed of insoluble non-nucleoside reverse transcriptase inhibitors exhibit strong anti-HIV activity.

Anita Leporati1, Mikhail S Novikov2, Vladimir T Valuev-Elliston3, Sergey P Korolev4, Anastasia L Khandazhinskaya3, Sergey N Kochetkov3, Suresh Gupta1, Julian Goding1, Elijah Bolotin5, Marina B Gottikh4, Alexei A Bogdanov6.   

Abstract

Benzophenone-uracil (BPU) scaffold-derived candidate compounds are efficient non-nucleoside reverse transcriptase inhibitors (NNRTI) with extremely low solubility in water. We proposed to use hydrophobic core (methoxypolyethylene glycol-polylysine) graft copolymer (HC-PGC) technology for stabilizing nanoparticle-based formulations of BPU NNRTI in water. Co-lyophilization of NNRTI/HC-PGC mixtures resulted in dry powders that could be easily reconstituted with the formation of 150-250 nm stable nanoparticles (NP). The NP and HC-PGC were non-toxic in experiments with TZM-bl reporter cells. Nanoparticles containing selected efficient candidate Z107 NNRTI preserved the ability to inhibit HIV-1 reverse transcriptase polymerase activities with no appreciable change of EC50. The formulation with HC-PGC bearing residues of oleic acid resulted in nanoparticles that were nearly identical in anti-HIV-1 potency when compared to Z107 solutions in DMSO (EC50=7.5±3.8 vs. 8.2±5.1 nM). Therefore, hydrophobic core macromolecular stabilizers form nanoparticles with insoluble NNRTI while preserving the antiviral activity of the drug cargo.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Benzophenone-uracyl; Copolymer; HIV-1; Microbicide; Nanoparticle; Non-nucleoside reverse transcriptase inhibitors

Mesh:

Substances:

Year:  2016        PMID: 27456163      PMCID: PMC5116409          DOI: 10.1016/j.nano.2016.07.004

Source DB:  PubMed          Journal:  Nanomedicine        ISSN: 1549-9634            Impact factor:   5.307


  32 in total

1.  pH-responsive nanoparticles releasing tenofovir intended for the prevention of HIV transmission.

Authors:  Tao Zhang; Timothy F Sturgis; Bi-Botti C Youan
Journal:  Eur J Pharm Biopharm       Date:  2011-06-26       Impact factor: 5.571

2.  A nanoparticle-encapsulated non-nucleoside reverse-transcriptase inhibitor with enhanced anti-HIV-1 activity and prolonged circulation time in plasma.

Authors:  Wen Li; Qian Wang; Yuan Li; Fei Yu; Qi Liu; Bingjie Qin; Lan Xie; Lu Lu; Shibo Jiang
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

3.  Polymer nanoparticles encapsulating siRNA for treatment of HSV-2 genital infection.

Authors:  Jill M Steinbach; Caroline E Weller; Carmen J Booth; W Mark Saltzman
Journal:  J Control Release       Date:  2012-06-15       Impact factor: 9.776

4.  Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004).

Authors:  Ian McGowan; Kailazarid Gomez; Karen Bruder; Irma Febo; Beatrice A Chen; Barbra A Richardson; Marla Husnik; Edward Livant; Clare Price; Cindy Jacobson
Journal:  AIDS       Date:  2011-05-15       Impact factor: 4.177

5.  Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1.

Authors:  E J Platt; K Wehrly; S E Kuhmann; B Chesebro; D Kabat
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

Review 6.  Mucus penetrating nanoparticles: biophysical tool and method of drug and gene delivery.

Authors:  Laura M Ensign; Craig Schneider; Jung Soo Suk; Richard Cone; Justin Hanes
Journal:  Adv Mater       Date:  2012-07-24       Impact factor: 30.849

7.  Powder for reconstitution of the anti-HIV-1 drug TMC278 - Formulation development, stability and animal studies.

Authors:  Elke Van Gyseghem; Murali Pendela; Lieven Baert; Jan Rosier; Gerben Van 't Klooster; Hilde De Man; Marie-Paule Bouche; Laurent Schueller; Pieter Van Remoortere; Piet Wigerinck; Erwin Adams; Jos Hoogmartens; Guy Van den Mooter
Journal:  Eur J Pharm Biopharm       Date:  2008-07-09       Impact factor: 5.571

Review 8.  Nanoparticle-based drug delivery to the vagina: a review.

Authors:  Laura M Ensign; Richard Cone; Justin Hanes
Journal:  J Control Release       Date:  2014-05-14       Impact factor: 9.776

Review 9.  Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability.

Authors:  Iris Usach; Virginia Melis; José-Esteban Peris
Journal:  J Int AIDS Soc       Date:  2013-09-04       Impact factor: 5.396

10.  Combination antiretroviral drugs in PLGA nanoparticle for HIV-1.

Authors:  Christopher J Destache; Todd Belgum; Keith Christensen; Annemarie Shibata; Akhilesh Sharma; Alekha Dash
Journal:  BMC Infect Dis       Date:  2009-12-09       Impact factor: 3.090

View more
  4 in total

1.  Antiretroviral Hydrophobic Core Graft-Copolymer Nanoparticles: The Effectiveness against Mutant HIV-1 Strains and in Vivo Distribution after Topical Application.

Authors:  Anita Leporati; Suresh Gupta; Elijah Bolotin; Gerardo Castillo; Joshua Alfaro; Marina B Gottikh; Alexei A Bogdanov
Journal:  Pharm Res       Date:  2019-03-27       Impact factor: 4.200

2.  New Derivatives of 5-Substituted Uracils: Potential Agents with a Wide Spectrum of Biological Activity.

Authors:  Vasily A Kezin; Elena S Matyugina; Mikhail S Novikov; Alexander O Chizhov; Robert Snoeck; Graciela Andrei; Sergei N Kochetkov; Anastasia L Khandazhinskaya
Journal:  Molecules       Date:  2022-04-30       Impact factor: 4.927

3.  Uracil-Containing Heterodimers of a New Type: Synthesis and Study of Their Anti-Viral Properties.

Authors:  Anna A Maslova; Elena S Matyugina; Robert Snoeck; Graciela Andrei; Sergey N Kochetkov; Anastasia L Khandazhinskaya; Mikhail S Novikov
Journal:  Molecules       Date:  2020-07-23       Impact factor: 4.411

Review 4.  Nanotechnology for virus treatment.

Authors:  Jiarong Zhou; Nishta Krishnan; Yao Jiang; Ronnie H Fang; Liangfang Zhang
Journal:  Nano Today       Date:  2020-12-01       Impact factor: 20.722

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.